Adage Capital Partners’s Benitec Biopharma BNTC Stock Holding History

Adage Capital Partners’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.6M	Hold	2,120,672	–	–	0.03%	436
2025 Q4	$28.6M	Buy	2,120,672 +148,148	+8%	+$2.05M	0.04%	385
2025 Q3	$27.7M	Hold	1,972,524	–	–	0.04%	382
2025 Q2	$23.1M	Hold	1,972,524	–	–	0.04%	409
2025 Q1	$25.7M	Hold	1,972,524	–	–	0.05%	363
2024 Q4	$24.9M	Buy	1,972,524 +1,131,129	+134%	+$12.2M	0.04%	382
2024 Q3	$7.73M	Hold	841,395	–	–	0.01%	666
2024 Q2	$5.88M	Buy	841,395 +652,207	+345%	+$4.81M	0.01%	692
2024 Q1	$993K	Hold	189,188	–	–	﹤0.01%	794
2023 Q4	$611K	Hold	189,188	–	–	﹤0.01%	778
2023 Q3	$572K	Buy	+189,188	New	+$588K	﹤0.01%	776

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Adage Capital Partners's BNTC Position: Q1 2026 in Review

Adage Capital Partners held its Benitec Biopharma (BNTC) position steady in Q1 2026 at 2,120,672 shares worth $22.6M. The position accounts for 0.03% of the portfolio, ranked #436.

Adage Capital Partners first reported a position in BNTC in Q3 2023 and has held it in 11 quarters since. The position peaked at $28.6M in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

Adage Capital Partners held 2,120,672 shares of Benitec Biopharma worth $22.6M as of Q1 2026.
Adage Capital Partners left its Benitec Biopharma share count unchanged in Q1 2026.
Benitec Biopharma made up 0.03% of Adage Capital Partners's portfolio in Q1 2026, its #436 holding.
Adage Capital Partners first reported a position in Benitec Biopharma in Q3 2023 and has held it in 11 quarters since.
Adage Capital Partners's Benitec Biopharma position peaked at $28.6M in Q4 2025.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.